Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Two Dupilumab Formulations in Healthy Volunteers
NCT05976373Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jan 2015
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dupilumab in atopic dermatitis (AD) (2 arms), sponsored by Sanofi. Primary endpoints: Maximum serum concentration of functional dupilumab at Day 57, Time to reach Cmax at Day 57 and 1 more. Started Jan 2015; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05976373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976373.